Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

Anónimo. Elvitegravir (Vitekta) for HIV. Med Lett Drugs Ther 2016;58:10-1. [Ref.ID 100789]

Anónimo. Loperamide (Imodium): Drug Safety Communication - Serious heart problems with high doses from abuse and misuse. U.S. Food and Drug Administration 2016:7 de junio. [Ref.ID 100377]

Cervero M, Torres R, Jusdado JJ, Pastor S, Agud JL. Factores predictivos de las interacciones farmacológicas clínicamente significativas en los pacientes tratados con regímenes basados en los inhibidores de la proteasa, inhibidores de transcriptasa inversa no nucleósidos y raltegravir. Med Clin (Barc) 2016;146:339-45. [Ref.ID 100173]

Anónimo. Elbasvir/grazoprevir (Zepatier) for hepatitis C. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:25-7. [Ref.ID 100126]

Anónimo. Disfunciones sexuales inducidas por fármacos. Butlletí de Farmacovigilància de Catalunya 2015;13:9-11. [Ref.ID 99831]

Anónimo. Abordaje de la hepatitis C. ¿Tiempos para la esperanza?. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-10. [Ref.ID 99823]

Anónimo. Daclatasvir (Daklinza) for HCV genotype 3 infection. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:142-3. [Ref.ID 99813]

Curry MP, O'Leary JG, Bzowei N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RSJr, Charlton M, ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-28. [Ref.ID 99805]

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeumem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, ASTRAL-2 Investigators, ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17. [Ref.ID 99804]

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5 and 6 infection. N Engl J Med 2015;373:2599-607. [Ref.ID 99803]

Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Sofosbuvir with velpatasvir in treatment-naive noncirrhtoic patients with genotype 1 to 6 hepatitis C infection: a randomized trial. Ann Intern Med 2015;163:818-26. [Ref.ID 99791]

Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CAM, Reddy KR, Roberts SK. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitic C virus infection: a randomized trial. Ann Intern Med 2015;163:809-17. [Ref.ID 99790]

Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]

Anónimo. Darunavir + cobicistat. Prescrire 2015;35:649. [Ref.ID 99709]

Anónimo. Cobicistat. Prescrire 2015;35:648-9. [Ref.ID 99708]

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, for the ALLY-2 Investigators. Daclastavir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-25. [Ref.ID 99507]

Naggie S, Cooper C, Saag M, Workowski K, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13. [Ref.ID 99506]

Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-23. [Ref.ID 99485]